CD274 and cervical cancer: Another promising antibody tested and proven in an EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study, an open-label, multicenter, phase 3 trial, is cemiplimab (anti-PD-1), which most recently achieved a 3.5 month improvement in OS with an acceptable side effect profile as a monotherapy, regardless of PD-L1 status, in advanced cervical cancer [58].